Your Complete Guide to Global Clinical Research and GCP Compliance
How to Design Coding, Case Narratives & Follow-Up That Meets FDA, EMA and MHRA Expectations How to Design Coding, Case Narratives & Follow-Up That Meets FDA, EMA and MHRA Expectations Designing effective coding, case narratives, and follow-up systems is crucial for clinical trial logistics and ensuring compliance with regulatory expectations set forth by agencies such…
Coding, Case Narratives & Follow-Up in Practice: Step-by-Step Guide for Sponsors and CROs Coding, Case Narratives & Follow-Up in Practice: Step-by-Step Guide for Sponsors and CROs In the rapidly evolving landscape of clinical research, especially with the rise of virtual clinical trials companies, understanding the intricacies of coding, case narratives, and follow-up processes is paramount…
Data Quality and Reconciliation Controls for Robust SUSAR Detection & Expedited Reporting Data Quality and Reconciliation Controls for Robust SUSAR Detection & Expedited Reporting In the context of clinical trials, the identification, reporting, and management of Suspected Unexpected Serious Adverse Reactions (SUSARs) is critical for ensuring participant safety and regulatory compliance. This step-by-step tutorial guide…
Global Considerations for SUSAR Detection & Expedited Reporting Across US, EU and UK Programs Global Considerations for SUSAR Detection & Expedited Reporting Across US, EU and UK Programs In the arena of clinical trials, rigorous monitoring and reporting of adverse events are crucial for ensuring participant safety and maintaining regulatory compliance. Among these adverse events…
Future Trends: AI, Automation and Real-World Data in SUSAR Detection & Expedited Reporting In the evolving landscape of clinical trials, particularly regarding the complexities surrounding serious unexpected suspected adverse reactions (SUSARs), there is a growing emphasis on utilizing technologies like artificial intelligence (AI), automation, and real-world data (RWD) to enhance detection and expedite reporting processes….
Integrating SUSAR Detection & Expedited Reporting With DSURs, PBRERs and Risk Management Plans Integrating SUSAR Detection & Expedited Reporting With DSURs, PBRERs and Risk Management Plans In the landscape of clinical trials, particularly those involving pharmaceuticals and biologics, the management of adverse events and reporting criteria has evolved significantly. As clinical operations, regulatory affairs, and…
Vendor and Partner Oversight Considerations in SUSAR Detection & Expedited Reporting Vendor and Partner Oversight Considerations in SUSAR Detection & Expedited Reporting Understanding the Regulatory Framework In the realm of clinical trials, particularly those related to alopecia areata clinical trials, robust regulatory frameworks govern the handling of adverse events, notably the identification and reporting of…
Read More “Vendor and Partner Oversight Considerations in SUSAR Detection & Expedited Reporting” »
Training Investigators and Sites to Execute SUSAR Detection & Expedited Reporting Reliably Training Investigators and Sites to Execute SUSAR Detection & Expedited Reporting Reliably In the context of clinical trials, recognizing and reporting Serious Unexpected Serious Adverse Reactions (SUSARs) is a critical component of patient safety and regulatory compliance. This detailed guide aims to equip…
Inspection-Ready Documentation Standards for SUSAR Detection & Expedited Reporting Inspection-Ready Documentation Standards for SUSAR Detection & Expedited Reporting In today’s complex landscape of clinical research, the accurate and timely reporting of Suspected Unexpected Serious Adverse Reactions (SUSARs) is of paramount importance. Regulatory bodies like the FDA, EMA, and MHRA require comprehensive documentation standards to ensure…
Read More “Inspection-Ready Documentation Standards for SUSAR Detection & Expedited Reporting” »
KRIs, KPIs and Dashboards to Monitor SUSAR Detection & Expedited Reporting Across Portfolios KRIs, KPIs and Dashboards to Monitor SUSAR Detection & Expedited Reporting Across Portfolios The monitoring of Serious Unexpected Suspected Adverse Reactions (SUSARs) is essential in clinical trials to ensure patient safety and regulatory compliance. In this step-by-step tutorial, we will delve into…